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Abstract
Understanding the link between vaccine immunogenicity and efficacy is currently a major focus in HIV research.
Consequently, recent developments in the HIV-1 vaccine field have led to a closer look at immune responses to
known efficacious vaccines. We undertook a study to explore clinical predictors of vaccine efficacy following
recombinant hepatitis B (rHBV) vaccination in a cohort of HIV-uninfected, hepatitis B virus naïve women living in a
peri-urban setting in Cape Town. Our aim was to define host biological risk factors associated with lack of vaccine
uptake. We found a significant association (p=0.009) between body mass index (BMI) and lack of vaccine-specific
IgG titre (<10mIU/mL). Obese individuals (BMI ≥ 30kg/m2) were significantly more likely to be non-responders
following 2 rHBV vaccine doses (Adjusted Odds Ratio of 8.75; p=0.043). There was no observed association
between vaccine responses and age, method of contraception or time from vaccination to antibody measurement.
These data suggest that obesity-associated factors interfere with vaccine immunogenicity and possible efficacy.
Citation: Young KM, Gray CM, Bekker L-G (2013) Is Obesity a Risk Factor for Vaccine Non-Responsiveness? PLoS ONE 8(12): e82779. doi:10.1371/
journal.pone.0082779
Editor: Sunil K Ahuja, South Texas Veterans Health Care System and University Health Science Center San Antonio, United States of America
Received July 5, 2013; Accepted October 28, 2013; Published December 11, 2013
Copyright: © 2013 Young et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was funded by the HIV Vaccine Trials Network (UM1 A1068614) SHAPe Program supported by the National Institutes of Allergy
and Infectious Disease, US National Institutes of Health; and the Fogarty International Center (http://www.hvtn.org/science/awards.html). The funders had
no role in the study design, data collection and analysis or decision to publish, and played only a minor role in preparation of the manuscript. An early draft
of the manuscript was reviewed by members of the HIV Vaccine Trials Network (HVTN) Protocol Committee. Suggestions from the committee were taken
into consideration in finalization of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: young.katherinem@gmail.com
Introduction
Two large HIV-1 vaccine trials have pointed to host factors
being important in predicting vaccine efficacy. The Step Study,
assessing the efficacy of the Merck Adenovirus type 5-vectored
HIV-1 vaccine (MRKAd5), found Ad5 sero-positivity and lack of
male circumcision to be associated with HIV-1 infection in men
who have sex with men vaccine recipients [1], while the RV144
HIV vaccine trial conducted in Thailand demonstrated higher
vaccine efficacy in individuals reporting lower risk sexual
behaviour [2]. These associations suggest that pre-vaccination
biological risk factors within the vaccine recipient might play a
significant role in the generation of protective immune
responses and that understanding these factors could be of
importance in the development of an effective vaccine. By
taking a “new” look at some “old” established efficacious
vaccines, we may find clues as to how best to elicit a protective
response to HIV-1 vaccines.
Hepatitis B Virus (HBV) in adults is predominantly sexually
acquired and individuals at risk of infection are similarly at risk
of acquiring HIV. The HBV vaccine is safe and effective with a
known correlate of protection and has been widely used
globally since its availability in 1982, with its inclusion in the
South African Expanded Program of Immunization (EPI)
schedule since 1995. The vaccine is a multi-dose, viral protein
subunit vaccine containing HBV surface antigen (HBsAg) and
an IgG response to this region is known to confer protection
from infection. The outcomes of the RV144 HIV-1 vaccine trial
in Thailand [2] and the subsequent immune-correlates analysis
[3], suggest that an effective HIV vaccine will require a multi-
dose, prime-boost regimen that elicits an IgG response to the
V1V2 region of the Env protein. Our premise is that an rHBV
vaccine could be used as a model to identify biological factors
in vaccine recipients which might impact on efficacy and so
provide insight into population variability which could be
important for translating to the development of an HIV vaccine.
Several studies have been conducted in healthy populations
in other parts of the world that have identified clinical predictors
of a seroprotective response to rHBV. Estévez et al. showed
that normal BMI (≤25kg/m2) and age <39 years were
associated with higher seroprotection rates in healthy Cuban
adults [4] and other studies have demonstrated that older age,
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male gender, obesity and smoking were associated with lower
seroprotection rates [5,6] and lower HBsAb responses [7].
A robust and effective public health vaccine intervention
programme to tackle the burden of infectious diseases in South
Africa is crucial to maintain and expand particularly with regard
to infections such as Tuberculosis (TB) and HIV. The parallel
burden of non-communicable diseases, such as obesity [8,9],
is also of concern, as this may be one biological factor which
could impact on vaccine uptake and efficacy. As South Africa is
poised to undertake large-scale HIV-1 vaccine efficacy trials, it
is relevant to examine characteristics of vaccine volunteers that
associate with vaccine non-responsiveness. Therefore, we
asked whether obesity is associated with vaccine non-
responsiveness using a known efficacious rHBV vaccine in a
population likely to be involved in pending HIV vaccine trials.
Methods
Ethical Considerations
Study participants were identified from a database of
potential participants for HIV prevention trials. All participants
provided written informed consent prior to the collection of any
participant data to be included in the database. Ethical
approval for the study to establish the database was obtained
from the Human Research Ethics Committee at the University
of Cape Town. Data included in this analysis were extracted
anonymously from the database.
Study Design and Participants
The study made use of existing data collected from HBV-
naïve HIV uninfected women at high risk for HIV infection who
had been vaccinated with the rHBV vaccine (Engerix-B®,
GlaxoSmithKline) prior to being screened for an HIV pre-
exposure prophylaxis study being conducted at the research
centre. Women aged 18 years or older, living in a peri-urban
setting outside Cape Town, who had received at least two of
the three scheduled doses of Engerix-B® at least 1 month apart
and had anti-HBV surface antigen titres (HBsAb) measured at
least 4 weeks after the second vaccination but prior to the third,
were included in the study. All participants subsequently went
on to receive the third dose of vaccine. HBsAb titres were
measured using a standard validated serological assay and the
reportable range for HBsAb titre was 10-1000mIU/mL.
Participants with HBsAb titres below 10mIU/mL were reported
as “<10mIU/mL” and those with titres above 1000mIU/mL were
reported as 1000mIU/mL. HBsAb<10mIU/mL were assigned a
value of 5mIU/mL for data analysis. A protective antibody titre
(seroprotection) was defined as HBsAb≥10mIU/mL [10]. A
detailed medical history was obtained for each participant prior
to vaccination and a complete physical examination performed.
No participants reported any acute illness at the time of
vaccination.
Statistical Considerations
The primary outcome variable was the presence or absence
of a seroprotective vaccine response to the rHBV vaccine. We
regarded this to be of greater clinical relevance than individual
antibody titres to associate predictors of vaccine failure.
Primary predictor variables included age, BMI, type of
contraceptive used at baseline and time from administration of
second vaccine dose to measurement of HBsAb titre. Reported
co-morbid illnesses were considered for inclusion in the
analysis. Descriptive statistics were computed for all variables
as follows: for categorical variables, the number and
percentage in each category; for continuous non-normally
distributed variables, median, quartiles and range. None of the
variables were normally distributed. Bivariate analyses were
performed using Spearman’s correlation test statistic and the
Mann-Whitney U-test for continuous and dichotomous
variables respectively. Fisher’s exact test was used for
variables with 3 or more categories. Multivariate logistic
regression was used to adjust for multiple predictors of vaccine
non-response.
Results
Of the 123 eligible participants, 25 (20%) had antibody titres
<10mIU/mL and were deemed non-responders, while the
remaining 80% were responders who demonstrated a
seroprotective response [range: 10mIU/mL – upper limit of
detection (1000mIU/mL)]. Participants were generally healthy
with only 17 participants reporting any co-morbid chronic
illnesses at baseline. Eight (8) participants had hypertension
controlled with medication at baseline and 7 participants
reported a history of non-severe asthma. Other reported
conditions were allergic rhinitis (n=2), atopic eczema (n=2) and
oral herpes simplex (n=1). Two (2) participants had both
asthma and hypertension and 1 had asthma and atopic
eczema. No participants had diabetes and none reported a
history of previous hepatitis. No associations were observed
between any reported chronic illness and vaccine response.
Three quarters of the participants were under 30 years of
age, with the oldest being 49 years old at the time of first
vaccination. Time from second vaccination to measurement of
HBsAb ranged from 29 to 314 days with the three quarters
being tested within approximately 2 months (63 days) (Table
1). Neither age nor time to HBsAb measurement were
significantly different between response groups (unadjusted
p=0.15 and p=0.77 respectively, Table 1). No significant
differences between contraceptive methods at baseline
(classified as none/non-hormonal, oral or long-acting injectable
contraceptives) were observed between response groups
(Fisher’s exact test p=0.24, Table 1). A significant association
was however identified between body mass index (BMI) and a
seroprotective antibody response. Non-responders were seen
to have significantly higher BMI than those who generated a
protective response (p=0.009, table 1, Figure 1A). BMI was
also seen to correlate weakly with age (Figure 1B) with older
women being relatively heavier than younger women (rs=0.26;
p=0.005). No significant relationships were observed between
other predictor variables.
When we divided participants into standard WHO defined
BMI categories: Underweight (<18.5kg/m2), normal weight
(18-5 – 24.9kg/m2), overweight (25 – 29.9kg/m2) and obese
(≥30kg/m2), no significant differences in BMI were observed
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between response group within each category, however, obese
non-responders had a tendency to higher BMI than responders
(Table 1). The underweight category was excluded from this
and all subsequent analyses given the small sample size (n=4).
Examination of the outcomes in terms of proportions of
response revealed a significant difference in vaccine response
between BMI categories (Fisher’s exact test; p=0.035).
Individuals with normal BMI had a 96% response rate versus
81% and 73% in the overweight and obese groups respectively
(Figure 2).
Based on these data, we built two multivariate logistic
regression models using forward selection, one included BMI
as a continuous variable, the second evaluated relative
differences between BMI categories. Age was included as a
potential confounder although it did not significantly improve
the model. No other possible predictors significantly improved
either model. The final model therefore included age and BMI
in either form (Table 2). From model 1 we see an 11% increase
in odds of a non-response with each 1kg/m2 increase in BMI
within our study population. Model 2 similarly demonstrated
that obese individuals were significantly more likely to be non-
responders following 2 rHBV vaccine doses (OR 8.75;
p=0.043). Being in the overweight category was not associated
with any difference in rate of seroprotection when compared
with normal weight individuals (OR=5.64; p=0.12) (Figure 2).
Discussion
This was a retrospective study to ask the question whether
obesity was associated with vaccine efficacy, using a known
efficacious rHBV, in a vaccine-volunteer population most likely
to also participate in future HIV vaccine trials. It is known that
four factors most commonly associate with vaccine non-
responsiveness; age, BMI or obesity, male gender and
smoking [4–7,10]. Although we only investigated for the effect
of age and BMI of these previously described risk factors, we
did assess the impact of hormonal contraceptives. Our data
revealed no association with age, although this might be due to
the relatively narrow age range of participants and the
predominance of women under the age of 30 years. We also
showed no link between vaccine response and contraceptive
type at baseline. Our study was limited by the retrospective
nature of the study design and the post hoc analysis of the
data.
Our finding that BMI, particularly over 30kg/m2 is associated
with an increased risk of non-responsiveness to the rHBV
vaccine is in agreement with findings from other populations
[4–7]. A possible explanation for this phenomenon could be a
distribution effect, in which case a different mode of delivery or
different needle length may need to be used. A study in obese
adolescents [11] showed that increasing the needle length in
delivering the vaccine “rescued” a proportion of non-
responders but did not account entirely for the lower response
rates in obese individuals. An alternative possibility is that there
could be more complex biological mechanisms at play and we
speculate that there is a relationship between obesity,
inflammation and vaccine immunogenicity.
Obesity is increasingly being recognised as a low-grade
chronic inflammatory condition [12–14] and it is possible that
obese individuals exist in a pro-inflammatory state, which
interferes with immunogenicity to vaccine candidates. The
negative impact of obesity on vaccine immune outcomes have
been shown for seasonal trivalent influenza vaccines (TIV) [15]
and the tetanus toxoid (TT) vaccine [16]. It is also possible that
differences in dietary intake may have an effect on the gastro-
Table 1. Summary statistics by response group.
Variable Responder Non-responder Mann-Whitney U-test
 N (%) Median (IQR) N (%) Median (IQR)  
Age (years) 98 (80) 24 (20-29) 25 (20) 26 (22-34) p=0.15
BMI (kg/m2) 98 (80) 28.40 (24.22-33.06) 24 (20) 32.66 (27.39-40.26) p=0.009*
BMI Categories     P=0.035*$
 • Underweight (<18.5 ) 3 (75) 18.29 (16.81-18,37) 1 (25) 17.22 (N/A) P=0.65
 • Normal (18.5-24.9) 25 (96) 21.83 (21.26-23.37) 1 (4) 22.66 (N/A) P=0.79
 • Overweight (25-29.9) 30 (81) 27.73 (26.49-28.83) 7 (19) 27.30 (26.89-28.25) P=0.76
 • Obese (>30) 40 (73) 33.98 (31.64-38.19) 15 (27) 38.01 (33.31-45.09) P=0.059
Days post vaccination 98 (80) 41 (33-62) 25 (20) 37 (34-66) p=0.77
HBsAb titre (GMT / 95%CI) 98 (80) 72.61 (57.71-91.37)    
Contraception 98 (80)  25 (20)   
 • None/non-hormonal 31 (89)  4 (11)   
 • Oral combined pill 5 (83)  1 (17)  P=0.24$
 • Long-acting injectable 61 (75)  20 (25)   
Data are presented as N (number of participants with each predictor variable in the respective response groups) and percentage of total with that predictor. BMI (Body Mass
Index); HBsAb (Hepatitis B surface antibody); GMT (Geometric mean titre). IQR (Interquartile Range). * Illustrates p-value≤ 0.05. $ Fisher’s exact test p-value. [Underweight
category not included in calculation of Fisher’s exact test p-value due to the small sample size (n=4)].
doi: 10.1371/journal.pone.0082779.t001
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Figure 1.  Associations of body mass index (BMI).  (A) Box-and-whisker plot showing the relative distribution of BMI by vaccine
response group (median, Interquartile range, minimum and maximum shown) (B) Spearman’s correlation of age at first vaccination
and BMI.
doi: 10.1371/journal.pone.0082779.g001
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intestinal microbiota, and this in turn can affect the “leakiness”
of the gut leading to bacterial translocation and increased
levels of immune activation [17–20]. Whatever the mechanistic
link between obesity, inflammation and vaccine non-
responsiveness might be, the fact is that obesity is on the rise
globally, and the 2003 South African Demographic and Health
survey defined 55% of women and 30% of men as either
overweight or obese based on BMI [9]. A later 2009/2010
survey commissioned by glaxosmithkline also associated a
higher likelihood of being overweight or obese with being less
affluent [21].
Understanding the mechanism underlying the relationship
between obesity and immune response to vaccines is of
importance in the development of all future vaccines including
an effective HIV-1 vaccine. Additionally, efficacy of existing
vaccines may be eroded as obesity increasingly becomes a
problem. Further studies are obviously required to unravel this
relationship.
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Figure 2.  Relative distribution of vaccine non-response by body mass index (BMI) category.  Illustrates the proportion of non-
responders within each standard BMI category. The underweight category has been excluded as only 4 participants fell into this
group.
doi: 10.1371/journal.pone.0082779.g002
Table 2. Multivariate Analysis of predictors of non-response to recombinant hepatitis B vaccine.
Predictor Odds Ratio (OR) 95% Confidence Interval   p-value
Model 1  
Age (years) 1.01 0.95 - 1.07 0.76
BMI# (kg.m2) 1.11 1.04 - 1.20 0.003*
Model 2  
Age (years) 1.02 0.96 - 1.08 0.60
Overweight relative to normal weight 5.64 0.65 - 49.20 0.12
Obese relative to normal weight 8.75 1.07 - 71.60 0.043*
Model 1 shows the logistic regression of vaccine non-response using BMI as a continuous variable#. Model 2 shows the same logistic regression if the BMI is categorised.
BMI (Body Mass Index). *Illustrates p-value≤0.05
doi: 10.1371/journal.pone.0082779.t002
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